A multicenter, prospective observational study of chemotherapy in elderly patients with biliary tract cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium.

In Study 22, the tremelimumab/Imfinzi regimen achieved a median overall survival (OS) of 18.7 months, a finding which AZ’s head of oncology R&D José Baselga said could “change the treatment ...

Methods: Patients with unresectable stage II/III NSCLC were eligible for inclusion. Patients received either one cycle of tremelimumab (75mg) with two cycles of durvalumab (1500mg) in cohort I, one ...

AstraZeneca’s development of checkpoint inhibitor combination Imfinzi and tremelimumab has chalked up serial trial failures in the last few years, but it finally has a positive result in lung ...

Tremelimumab is under clinical development by AstraZeneca and currently in Phase II for Bladder Cancer. According to GlobalData, Phase II drugs for Bladder Cancer have a 31% phase transition success ...

前言肝细胞癌（HCC）是全球癌症相关死亡的主要原因。由于其复发率高，且缺乏有效的控制药物，5年生存率仅为10%左右。近年来，免疫疗法在治疗实体瘤方面取得了重大突破。各种免疫疗法，如免疫检查点抑制剂（ICIs），包括联合疗法，已在临床应用和研究中显示出 ...

Mitchell, JD ∙ Cehic, DA ∙ Morgia, M ∙ et al.

研究显示，抗体偶联药物（ADC）与免疫检查点抑制剂的联合用药有望提高肿瘤患者的临床获益。此次阿斯利康中国与宜联生物的深度合作，有望为多种实体瘤的临床治疗探索进一步的可能性，为肿瘤患者提供更多创新治疗选择。

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For over a century ...